文献速递妇科

ARID1A突变/缺失与卵巢透明细胞癌高免疫原性特征相关

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-07-14

该研究对103例不同组织学亚型卵巢癌进行160个癌症相关基因测序及ARID1A、PD-L1、CD8免疫组化分析。结果显示ARID1A突变在透明细胞癌中与高PD-L1、CD8水平及高肿瘤突变负荷相关,但在子宫内膜样癌中无此关联。ARID1A状态可作为透明细胞癌免疫检查点阻断治疗的候选生物标志物。

要点

  • ARID1A突变在透明细胞癌中与高PD-L1和CD8水平相关(p<0.001)。
  • ARID1A缺失在透明细胞癌和高浆乳癌中与高PD-L1或CD8相关(p<0.001)。
  • ARID1A状态或可指导透明细胞癌免疫检查点抑制剂的选择。

核心结论

  • ARID1A突变/表达与透明细胞癌的免疫微环境因素相关,但在子宫内膜样癌中无此关联。
  • ARID1A状态可作为透明细胞癌免疫检查点阻断治疗的候选生物标志物。

研究设计与样本

  • 对103例不同组织学亚型卵巢癌进行160个癌症相关基因的下一代测序。
  • 分析ARID1A、PD-L1和CD8的免疫组化状态与生存的关系。

主要发现

  • ARID1A突变率:高浆乳癌0%(n=36)、透明细胞癌41.5%(n=41)、子宫内膜样癌45.0%(n=20)、黏液性癌33.3%(n=6)。
  • ARID1A缺失率:高浆乳癌19.4%、透明细胞癌75.6%、子宫内膜样癌60.0%、黏液性癌0%。
  • 透明细胞癌中ARID1A突变与高PD-L1(p<0.001)或CD8水平(p<0.001)相关。
  • 透明细胞癌中ARID1A缺失与高PD-L1或CD8水平相关(p<0.001),高浆乳癌中亦相关(p<0.001)。
  • 透明细胞癌中ARID1A突变与高肿瘤突变负荷相关(p=0.006)。

临床怎么用

  • 在透明细胞癌中可检测ARID1A状态以辅助筛选免疫检查点阻断治疗的潜在获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: ARID1A mutation is frequently found in clear cell ovarian cancer (CCC) and endometrioid ovarian cancer (EC). Anti-PD-1 monotherapy has been found to have limited efficacy in epithelial ovarian cancer; however, anti-PD-1 therapy showed significant clinical benefit in some CCC. We sought to define the relationship of ARID1A mutation/ARID1A expression to the immunogenic profile of different histologic subtypes of ovarian cancer. METHODS: We performed next-generation sequencing of 160 cancer-related genes. Also, we analyzed the immunohistochemical status of ARID1A, PD-L1, and CD8 with survival in different histologic subtypes of ovarian cancer in a total of 103 cases. RESULTS: ARID1A mutation was found in 0% of the high-grade serous ovarian cancer (HGSC) (n = 36), 41.5% of the CCC (n = 41), 45.0% of the EC (n = 20), and 33.3% of the mucinous ovarian cancer (MC) (n = 6) cases. ARID1A loss was found in 19.4% of the HGSC, 75.6% of the CCC, 60.0% of the EC and 0% of the MC cases. ARID1A mutation was found to be associated with high PD-L1 (p < 0.001) or CD8 levels (p < 0.001) in CCC but not in other histologic subtypes. Meanwhile, ARID1A loss was associated with high PD-L1 or CD8 levels in CCC (p < 0.001) and HGSC (p < 0.001) but not in EC and MC. In addition, ARID1A mutation was associated with high tumor mutation burden in CCC (p = 0.006). CONCLUSIONS: ARID1A mutation/ARID1A expression is associated with immune microenvironmental factors in CCC but not in EC. ARID1A status can be a biomarker for selecting candidates for immune checkpoint blockade in CCC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kuroda Y, Chiyoda T, Kawaida M, et al. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer. Gynecol Oncol. 2021. PMID: 34272091. doi:10.1016/j.ygyno.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。